Corbus Pharmaceuticals (NASDAQ:CRBP) Upgraded to Sell at StockNews.com

Corbus Pharmaceuticals (NASDAQ:CRBP) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research report issued to clients and investors on Monday.

CRBP has been the subject of a number of other research reports. Wedbush restated an “outperform” rating and set a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, November 4th. Mizuho restated an “outperform” rating and issued a $74.00 target price on shares of Corbus Pharmaceuticals in a report on Friday, September 20th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Corbus Pharmaceuticals in a research note on Monday, September 23rd. Piper Sandler began coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They set an “overweight” rating and a $35.00 price objective for the company. Finally, B. Riley dropped their target price on Corbus Pharmaceuticals from $85.00 to $40.00 and set a “buy” rating on the stock in a report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $62.00.

Corbus Pharmaceuticals Stock Performance

Shares of NASDAQ CRBP traded down $0.49 during midday trading on Monday, hitting $11.30. 127,088 shares of the stock traded hands, compared to its average volume of 169,955. Corbus Pharmaceuticals has a one year low of $5.67 and a one year high of $61.90. The business has a 50 day moving average price of $15.26 and a two-hundred day moving average price of $32.72. The company has a market cap of $137.62 million, a PE ratio of -2.41 and a beta of 2.63.

Institutional Trading of Corbus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp purchased a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter valued at $1,368,000. Rhumbline Advisers purchased a new stake in Corbus Pharmaceuticals during the second quarter worth about $638,000. Victory Capital Management Inc. bought a new stake in Corbus Pharmaceuticals in the second quarter worth about $862,000. Acadian Asset Management LLC bought a new stake in Corbus Pharmaceuticals in the second quarter worth about $716,000. Finally, HighVista Strategies LLC purchased a new position in Corbus Pharmaceuticals in the second quarter valued at about $1,755,000. 64.64% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.